Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Sponsor
AstraZeneca
Study ID
NCT03133234
Status
Completed

Conditions

  • T790M Positive NSCLC Patients

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To assess the effectiveness and safety of osimertinib treatment in a real world setting.

Key Dates

Start date
May 23, 2017
Status verified
Nov 2018
Primary completion
Sep 13, 2017
Completion
Sep 13, 2017

Study Design

Enrollment
47 participants (actual)

Arms

  • Arm: EGFR T790M Patients
    Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI

Primary Outcome Measure

ORR [ Time Frame: Followed up with 6 months after last patient in ]